Trial Profile

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab+vibostolimab (Primary) ; Pemetrexed (Primary) ; Vibostolimab (Primary)
Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms KEYVIBE-001; MK-7684-001
Sponsors Merck Sharp & Dohme

Most Recent Events

06 Aug 2024 Status changed from active, no longer recruiting to completed.
11 Jul 2024 Planned End Date changed from 1 Aug 2024 to 24 Jul 2024.
11 Jul 2024 Planned primary completion date changed from 1 Aug 2024 to 24 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com